ADiTx Therapeutics Competitors

AbCellera Biologics (NASDAQ:ABCL) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AbCellera Biologics and ADiTx Therapeutics, as provided by MarketBeat.

AbCellera Biologics presently has a consensus price target of $52.80, suggesting a potential upside of 76.94%. Given AbCellera Biologics' higher possible upside, equities analysts plainly believe AbCellera Biologics is more favorable than ADiTx Therapeutics.

Earnings & Valuation

This table compares AbCellera Biologics and ADiTx Therapeutics' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares AbCellera Biologics and ADiTx Therapeutics' net margins, return on equity and return on assets.

Summary

AbCellera Biologics beats ADiTx Therapeutics on 2 of the 2 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for ADiTx Therapeutics and Sana Biotechnology, as provided by MarketBeat.

Sana Biotechnology has a consensus price target of $40.00, suggesting a potential upside of 54.38%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than ADiTx Therapeutics.

Valuation & Earnings

This table compares ADiTx Therapeutics and Sana Biotechnology's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ADiTx Therapeutics and Sana Biotechnology's net margins, return on equity and return on assets.

Summary

Sana Biotechnology beats ADiTx Therapeutics on 2 of the 3 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Abcam (NASDAQ:ABCM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for ADiTx Therapeutics and Abcam, as provided by MarketBeat.

Abcam has a consensus price target of $22.00, suggesting a potential upside of 11.68%. Given Abcam's higher probable upside, analysts clearly believe Abcam is more favorable than ADiTx Therapeutics.

Valuation & Earnings

This table compares ADiTx Therapeutics and Abcam's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ADiTx Therapeutics and Abcam's net margins, return on equity and return on assets.

Summary

Abcam beats ADiTx Therapeutics on 2 of the 3 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Seer (NASDAQ:SEER) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current recommendations for ADiTx Therapeutics and Seer, as provided by MarketBeat.

Seer has a consensus price target of $68.00, suggesting a potential upside of 22.08%. Given Seer's higher probable upside, analysts clearly believe Seer is more favorable than ADiTx Therapeutics.

Valuation & Earnings

This table compares ADiTx Therapeutics and Seer's revenue, earnings per share (EPS) and valuation.

Profitability

This table compares ADiTx Therapeutics and Seer's net margins, return on equity and return on assets.

Summary

Seer beats ADiTx Therapeutics on 2 of the 3 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Profitability

This table compares ADiTx Therapeutics and Nuvation Bio's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares ADiTx Therapeutics and Nuvation Bio's revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of current recommendations for ADiTx Therapeutics and Nuvation Bio, as provided by MarketBeat.

Nuvation Bio has a consensus price target of $17.40, suggesting a potential upside of 50.52%. Given Nuvation Bio's higher probable upside, analysts clearly believe Nuvation Bio is more favorable than ADiTx Therapeutics.

Summary

Nuvation Bio beats ADiTx Therapeutics on 2 of the 2 factors compared between the two stocks.

ADiTx Therapeutics (NASDAQ:ADTX) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, analyst recommendations and risk.

Profitability

This table compares ADiTx Therapeutics and ImmunityBio's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares ADiTx Therapeutics and ImmunityBio's top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of current recommendations and price targets for ADiTx Therapeutics and ImmunityBio, as reported by MarketBeat.

ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 37.51%. Given ImmunityBio's higher probable upside, analysts plainly believe ImmunityBio is more favorable than ADiTx Therapeutics.

Summary

ImmunityBio beats ADiTx Therapeutics on 1 of the 1 factors compared between the two stocks.